BILLION NOK COMBINED VALUE
OF PORTFOLIO COMPANIES
NEW LICENSE AGREEMENTS
NEW PATENT APPLICATIONS
NEW CLINICAL STUDIES
ONGOING CLINICAL STUDIES
NEW COMPANIES ESTABLISHED
MILLION NOK TO
BILLION NOK IN
PRIVATE CAPITAL RAISED
– how do you take your research to market?
Inven2’s main area of focus is taking research results and turning them into a product or service in a market. This is done through a value chain that starts with idea hunting and marketing of Inven2’s services aimed at researchers at the University of Oslo and Oslo University Hospital.Read more
Each year, Inven2 organises a wealth of activities intended to stimulate innovation. We hold some activities independently, but many take place in cooperation with players involved in the big ecosystem we are part of.
Collaboration between business and research is important to achieving more innovation and leads to more commercialisations. Inven2 has made targeted efforts on industry collaboration for close to two years through a number of different projects.Read more
CLINICAL TRIALS ARE THE KEY TO MEDICAL DEVELOPMENT
Clinical trials involve testing new drugs and medical equipment on human subjects. Clinical trials can be conducted on both healthy volunteers and patients.Read more
A word from the CEO
Inven2 is the biggest technology transfer office (TTO) in Norway, which means that we are responsible for assessing and commercialising innovative research conducted at the University of Oslo, Oslo University Hospital and the health trusts under South-Eastern Norway Regional Health Authority – i.e. our owners.
In 2019, my 31-strong staff and I worked hard to live up to this responsibility, as we have done now for almost ten years. Our efforts certainly bore fruit in 2019.Read more
Making a difference by transforming knowledge into products and services for the benefit of society.
Research and knowledge are the keys to addressing global challenges relating to health, climate and the environment. Highly capable researchers and clinicians from larger parts Norway report their ideas and discoveries to us. We develop and manage these ideas, and proceed with the ones that can be transformed into products that benefit society.
We have started businesses that develop better cancer therapies, combat antibiotic resistance and identify security breaches in complex IT systems. Two-thirds of our businesses and licences are in the field of life science, since the scientific community we represent is particularly strong in that field.
Another important area for us is to administer agreements on clinical trials on behalf of the hospitals in our region and in the northern part of Norway. We make active endeavours to get more international companies to carry out their clinical trials in Norway. That way, more innovative treatment can benefit more patients in Norway.
Inven2 is a limited company owned by the University of Oslo and Oslo University Hospital. Inven2 currently has 32 employees.
Cutting Edge 2019
CUTTING EDGE 2018
We are proud to co-organise the Cutting Edge Festival, Norway’s biggest science and technology event, where we present the latest in science, technology and innovation together with our partners Oslotech and the University of Oslo.www.cuttingedgefestival.no Watch film from Cutting Edge
CUTTING EDGE FESTIVAL IN NUMBERS
USEFUL AND IMPORTANT MATCMAKING AT CUTTING EDGE
Almost 90 1:1 meetings between researchers, mature companies and start-ups were held at this year’s Cutting Edge. ‘We received important feedback,’ says researcher Henriette Andresen after her meeting with Pfizer.Read more
Inven2 has a portfolio comprising 51 companies. Seven new companies were established in 2019, of which four were student companies and three aim to commercialise research-based innovation. Together, the companies are worth around NOK 12.5 billion. The companies raised a total of NOK 1.3 billion for development purposes in 2019. At the same time, NOK 40 million was ploughed back into research at the University of Oslo and Oslo University Hospital.
The value of the portfolio increased by a total of 29 per cent in 2019, due, among other things, to the listing of the cancer company Ultimovacs ASA and the increase in the value of the company Vaccibody AS. Vaccibody develops individually tailored cancer vaccines and presented very promising clinical data in November.
It is currently the most highly valued biotechnology company in Norway, with a grey market value of NOK 4.9 billion.
You can read more about Ultimovacs’ listing and the clinical development of the UV1 cancer vaccine below. You can also read more about the security company OffPAD, whose security solution is on the verge of a commercial breakthrough. The solution aims to prevent espionage and hacking of government and industry employees’ mobile phones and PCs while on official trips. The final company you can read more about is Serca Pharmaceuticals. Its goal is to develop an innovative treatment for heart attack patients, and it made important commercial steps towards that end in 2019.
The year 2019 also saw the sale of Prophylix Pharma AS, in which Inven2 has a stake, to the American company Rallybio. It develops drugs for the treatment of rare diseases.
Inven2 want to make a difference by transforming research and knowledge into products and services for the benefit of society. We have contributed to the launching of many products and services. Here is a selection.
Inven2 is part of a vital, ever-growing ecosystem in research and development. The area near Inven2’s premises in Oslo Science Park is home to a number of clusters and incubators, as well as the University of Oslo and Oslo University Hospital.Read more